ClinicalTrials.gg
CompletedNCT05347927Microbiome IIUpdated Jan 31, 2025

Observational Study to Evaluate the Influence of Undercast Material Types on Skin Microbiome

An observational study in Skin Microbiome and Undercast Materials, sponsored by BSN Medical GmbH. Completed at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by BSN Medical GmbH · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
108
Ages
18 Years and older
Sex
All
01

Study summary

This clinical study will evaluate the clinical performance and the safety of the CE-marked casting and padding materials when used in routine fracture care without any additional invasive methods and within the intended use. As primary objective the cast therapy´s influence on skin microbiome during fracture management will be investigated. Further, the influence of the padding material on the skin microbiome, device comfort, skin conditions, and impact on daily life activities as well as HCP´s and patient´s satisfaction and general product safety and performance are considered as secondary outcomes.

02

Conditions studied

  • Skin Microbiome
  • Undercast Materials
03

In context

Lead sponsor

BSN Medical GmbH is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Subjects with broken forwarm receiving short arm cast

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject ≥ 18 years of age
  2. Patient is physically and mentally able to participate in this study
  3. Proper understanding of the Dutch language
  4. Signed
  5. Fractures to be treated with a short-arm cast without thumb inclusion for the period of 3 weeks (e.g. 2R3A1 = radial styloid avulsion, 2R3A2 = Simple radial fracture, 2U3A1 = Ulnar fracture of the base of the styloid process, 2U3A2= Simple distal ulna fracture, 2R3B1 = Intraarticular fracture of the styloid process of the radius (not displaced) or Triquetrum fracture (non AO classified))

Exclusion criteria

Exclusion Criteria:

  1. Subject \<18 years of age
  2. Pregnancy, breast feeding
  3. Participation in other clinical trials
  4. Patient is neither physically nor mentally able to participate in this study
  5. Non-intact skin in treatment area (including dermatological issues)
  6. Patients with impaired (e.g. Cortisone skin, extremely dry skin, parchment skin) or damaged skin with either a surgical wound or a traumatic wound
  7. Medical treatment prior casting which could influence the microbiome
  8. Known Blood Circulatory Diseases
  9. Known Lymphedema or any general disorder of the lymphatic system
  10. Known Osteoporosis
  11. Known Diabetes
  12. Knowing of one of the following illnesses that might require regular systemic medication: cancer, rheumatic disease
  13. Intolerability or documented allergies against cast materials
  14. Subjects with not "normal" (unusual) hygienic behavior
  15. Suspected drug addiction or alcohol abuse
  16. Patients diagnosed -positive or with infectious hepatitis based on self-declaration by subjects
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
108 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Test group

    will receive water resistante padding and a cast

    Device: water resistante padding

  • Control group

    will receive traditional non-water resistante padding and cast

    Device: non water resistante padding

Interventions

  • Devicewater resistante padding

    * Delta-Dry® Softliner * Tensoban® * Delta-Dry®

  • Devicenon water resistante padding

    * Delta-Net® Stockinette * Delta-Rol®

06

What researchers measure

Primary outcomes

  1. products´ influence on skin microbiome during fracture management

    Quantity of bacteria in the skin microbiome

    Time frame: 3 weeks

  2. products´ influence on skin microbiome during fracture management

    Taxonomic composition of skin microbiome

    Time frame: 3 weeks

  3. products´ influence on skin microbiome during fracture management

    Alpha diversity of skin microbiome

    Time frame: 3 weeks

  4. products´ influence on skin microbiome during fracture management

    Beta diversity skin microbiome

    Time frame: 3 weeks

Secondary outcomes

  1. Number of adverse events during study per product

    Time frame: 3 weeks

  2. General product performance

    Time frame: 3 weeks

  3. Treatment comfort

    Time frame: 3 weeks

  4. Impact on daily life activities

    Time frame: 3 weeks

07

Study locations

3 sites
  • Ommelander Ziekenhuis
    Groningen, Scheemda 9679 BJ, Netherlands
  • Wilhelmina Ziekenhuis Assen (Assen, NL)
    Assen, 9401 RK, Netherlands
  • Leids Universitair Medisch Centrum (Leiden, NL)
    Leiden, 2333 ZA, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Sep 2024, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2022
First posted
Apr 27, 2022
StartActual
Oct 30, 2022
Primary completionActual
Sep 30, 2024
CompletionActual
Dec 31, 2024
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05347927
Lead sponsor
BSN Medical GmbH
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Oct 30, 2022
Primary completion
Sep 30, 2024
Completion
Dec 31, 2024
Last update
Jan 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion